CEL-SCI Corp. (NYSE American: CVM) believes boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in its global pivotal Phase 3 study, CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma (cancer) of the head and neck with Multikine (leukocyte interleukin, injection) first, before they received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine has received Orphan Drug Designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. Multikine is designed to help the immune system ‘see’ the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. For more information, visit the company’s website at cel-sci.com
About The LD 500
The LD 500 is the most ambitious project in LD Micro’s 14-year history of leading the micro-cap space as an independent resource. Investors will enjoy updates from hundreds of companies that represent a wide variety of industries. Featuring some of the most prominent companies in the micro-cap world, the LD 500 also incorporates interviews and keynotes with small-cap royalty.
To view InvestorBrandNetwork’s virtual coverage, which includes one-click access to market research tools on the presenting companies, visit: http://ibn.fm/TheLD500
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
